Kiniksa Pharmaceuticals International, plc Financials

KNSA

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Financial Profile 66/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Kiniksa Pharmaceuticals International, plc has an operating margin of -10.8%, meaning the company retains $-11 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -9.3% the prior year.

Growth

100

Kiniksa Pharmaceuticals International, plc's revenue surged 56.6% year-over-year to $423.2M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Kiniksa Pharmaceuticals International, plc carries a low D/E ratio of 0.32, meaning only $0.32 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 3.30, Kiniksa Pharmaceuticals International, plc holds $3.30 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

Kiniksa Pharmaceuticals International, plc has a free cash flow margin of 6.0%, earning a moderate score of 30/100. The company generates positive cash flow after capital investments, but with room for improvement.

Piotroski F-Score Weak

3/9

Kiniksa Pharmaceuticals International, plc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Mixed

-0.59x

For every $1 of reported earnings, Kiniksa Pharmaceuticals International, plc generates $-0.59 in operating cash flow ($25.7M OCF vs -$43.2M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

This page shows Kiniksa Pharmaceuticals International, plc (KNSA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

$423.2M

YoY+56.6%

Kiniksa Pharmaceuticals International, plc generated $423.2M in revenue in fiscal year 2024. This represents an increase of 56.6% from the prior year.

EBITDA

-$43.9M

YoY-92.2%

Kiniksa Pharmaceuticals International, plc's EBITDA was -$43.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 92.2% from the prior year.

Free Cash Flow

$25.4M

YoY+92.9%

Kiniksa Pharmaceuticals International, plc generated $25.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 92.9% from the prior year.

Net Income

-$43.2M

YoY-406.7%

Kiniksa Pharmaceuticals International, plc reported -$43.2M in net income in fiscal year 2024. This represents a decrease of 406.7% from the prior year.

EPS (Diluted)

$-0.60

YoY-400.0%

Kiniksa Pharmaceuticals International, plc earned $-0.60 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 400.0% from the prior year.

Cash & Debt

$183.6M

YoY+70.1%

5Y CAGR+31.4%

Kiniksa Pharmaceuticals International, plc held $183.6M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

N/A

Gross Margin

85.6%

YoY-2.0pp

Kiniksa Pharmaceuticals International, plc's gross margin was 85.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 2.0 percentage points from the prior year.

Operating Margin

-10.8%

YoY-1.5pp

Kiniksa Pharmaceuticals International, plc's operating margin was -10.8% in fiscal year 2024, reflecting core business profitability. This is down 1.5 percentage points from the prior year.

Net Margin

-10.2%

YoY-15.4pp

Kiniksa Pharmaceuticals International, plc's net profit margin was -10.2% in fiscal year 2024, showing the share of revenue converted to profit. This is down 15.4 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$111.6M

YoY+46.7%

5Y CAGR-3.7%

Kiniksa Pharmaceuticals International, plc invested $111.6M in research and development in fiscal year 2024. This represents an increase of 46.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$277K

YoY+113.1%

5Y CAGR-38.7%

Kiniksa Pharmaceuticals International, plc invested $277K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 113.1% from the prior year.

KNSA Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$423.2M+56.6%	$270.3M+22.7%	$220.2M+471.2%	$38.5M	N/A	N/A
Cost of Revenue	$60.9M+82.3%	$33.4M+45.9%	$22.9M+151.6%	$9.1M	N/A	N/A
Gross Profit	$362.3M+53.0%	$236.9M+20.1%	$197.3M+570.0%	$29.4M	N/A	N/A
R&D Expenses	$111.6M+46.7%	$76.1M+16.2%	$65.5M-34.0%	$99.3M-11.4%	$112.0M-17.0%	$135.0M
SG&A Expenses	$168.0M+29.8%	$129.4M+32.1%	$98.0M+14.0%	$85.9M+89.6%	$45.3M+29.6%	$35.0M
Operating Income	-$45.6M-81.0%	-$25.2M-357.8%	$9.8M+106.2%	-$156.6M+0.5%	-$157.4M+7.4%	-$170.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$7.0M+122.9%	-$30.7M+82.2%	-$172.3M-12543.1%	$1.4M-73.1%	$5.2M+351.7%	-$2.0M
Net Income	-$43.2M-406.7%	$14.1M-92.3%	$183.4M+216.1%	-$157.9M+2.1%	-$161.4M+0.3%	-$161.9M
EPS (Diluted)	$-0.60-400.0%	$0.20-92.3%	$2.60+213.0%	$-2.30+11.9%	$-2.61+12.7%	$-2.99

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$180.9M+15.3%	$156.8M+13.8%	$137.8M+12.4%	$122.5M+12.8%	$108.6M+36.0%	$79.9M-4.2%	$83.4M+24.4%	$67.0M
Cost of Revenue	$20.3M+8.9%	$18.6M+4.1%	$17.9M-0.2%	$17.9M+45.2%	$12.3M+16.4%	$10.6M+10.4%	$9.6M+5.5%	$9.1M
Gross Profit	$160.6M+16.2%	$138.2M+15.2%	$119.9M+14.6%	$104.6M+8.7%	$96.3M+39.0%	$69.3M-6.1%	$73.8M+27.4%	$58.0M
R&D Expenses	$24.2M+28.9%	$18.8M-3.0%	$19.3M-45.1%	$35.2M+46.6%	$24.0M-8.8%	$26.3M+31.3%	$20.1M+17.2%	$17.1M
SG&A Expenses	$49.1M+4.8%	$46.9M+7.7%	$43.5M+7.4%	$40.5M-4.4%	$42.4M+9.6%	$38.7M+5.3%	$36.7M+6.6%	$34.5M
Operating Income	$24.0M+19.2%	$20.2M+51.9%	$13.3M+168.8%	-$19.3M-16394.9%	-$117K+99.3%	-$16.5M-20522.2%	$81K+100.7%	-$10.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$8.7M+72.9%	$5.0M-28.2%	$7.0M+186.8%	-$8.1M-230.2%	$6.2M+81.2%	$3.4M+115.0%	-$22.8M-525.4%	$5.4M
Net Income	$18.4M+3.4%	$17.8M+108.8%	$8.5M+196.1%	-$8.9M-127.4%	-$3.9M+77.9%	-$17.7M-170.2%	$25.2M+282.2%	-$13.9M
EPS (Diluted)	$0.230.0%	$0.23+109.1%	$0.11+200.0%	$-0.11-83.3%	$-0.06+76.0%	$-0.25-167.6%	$0.37+285.0%	$-0.20

KNSA Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$580.6M+10.3%	$526.3M+14.5%	$459.7M+97.5%	$232.8M-33.4%	$349.5M+37.3%	$254.5M
Current Assets	$331.8M+20.1%	$276.3M+13.7%	$243.1M+23.7%	$196.4M-41.1%	$333.2M+37.9%	$241.6M
Cash & Equivalents	$183.6M+70.1%	$108.0M-12.0%	$122.7M+0.2%	$122.5M+7.4%	$114.0M+143.0%	$46.9M
Inventory	$26.4M-15.3%	$31.1M+44.1%	$21.6M+487.7%	$3.7M	$0	N/A
Accounts Receivable	$41.7M+96.2%	$21.3M+68.0%	$12.7M+217.7%	$4.0M	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$142.1M+62.5%	$87.5M+37.7%	$63.5M+33.0%	$47.8M+27.3%	$37.5M+28.9%	$29.1M
Current Liabilities	$100.6M+58.0%	$63.7M+35.3%	$47.1M+5.0%	$44.8M+40.8%	$31.8M+14.4%	$27.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$438.4M-0.1%	$438.8M+10.8%	$396.1M+114.1%	$185.0M-40.7%	$311.9M+38.4%	$225.4M
Retained Earnings	-$521.1M-9.0%	-$477.9M+2.9%	-$492.0M+27.1%	-$675.4M-30.5%	-$517.5M-45.3%	-$356.1M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$712.3M+7.7%	$661.1M+10.3%	$599.3M+3.2%	$580.6M+7.0%	$542.4M+4.4%	$519.7M-1.3%	$526.3M+9.0%	$483.1M
Current Assets	$475.5M+13.1%	$420.3M+18.1%	$355.9M+7.3%	$331.8M+10.2%	$301.0M+11.2%	$270.6M-2.1%	$276.3M+7.9%	$256.1M
Cash & Equivalents	$174.9M-8.9%	$192.0M+22.2%	$157.1M-14.4%	$183.6M+84.9%	$99.3M-29.6%	$141.1M+30.7%	$108.0M-8.4%	$117.8M
Inventory	$41.4M-14.1%	$48.2M+118.3%	$22.1M-16.3%	$26.4M-24.4%	$34.9M+27.8%	$27.3M-12.4%	$31.1M+21.7%	$25.6M
Accounts Receivable	$51.7M+62.1%	$31.9M-20.4%	$40.1M-4.0%	$41.7M+104.0%	$20.5M+27.9%	$16.0M-24.8%	$21.3M+599.3%	$3.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$176.9M+6.5%	$166.1M+17.1%	$141.8M-0.2%	$142.1M+32.4%	$107.3M+22.3%	$87.8M+0.3%	$87.5M+12.2%	$77.9M
Current Liabilities	$123.6M+4.9%	$117.8M+21.1%	$97.3M-3.3%	$100.6M+19.4%	$84.3M+31.3%	$64.2M+0.9%	$63.7M+19.1%	$53.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$535.4M+8.2%	$495.0M+8.2%	$457.5M+4.3%	$438.4M+0.8%	$435.1M+0.7%	$431.9M-1.6%	$438.8M+8.3%	$405.1M
Retained Earnings	-$476.3M+3.7%	-$494.8M+3.5%	-$512.6M+1.6%	-$521.1M-4.3%	-$499.6M-0.8%	-$495.7M-3.7%	-$477.9M+5.0%	-$503.2M

KNSA Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$25.7M+93.1%	$13.3M+129.1%	$5.8M+104.6%	-$126.3M+7.5%	-$136.5M+13.8%	-$158.4M
Capital Expenditures	$277K+113.1%	$130K+23.8%	$105K-74.7%	$415K+46.6%	$283K-91.2%	$3.2M
Free Cash Flow	$25.4M+92.9%	$13.2M+131.0%	$5.7M+104.5%	-$126.7M+7.4%	-$136.8M+15.3%	-$161.6M
Investing Cash Flow	$37.7M+227.5%	-$29.6M-265.9%	-$8.1M-106.3%	$128.6M+648.7%	-$23.4M-147.6%	$49.2M
Financing Cash Flow	$12.3M+720.5%	$1.5M-40.6%	$2.5M-57.2%	$5.9M-97.4%	$227.1M+170.0%	$84.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	$33.7M+19.9%	$28.1M+25.8%	$22.3M+18.9%	$18.8M+263.2%	$5.2M+29.6%	$4.0M-7.8%	$4.3M-74.5%	$17.0M
Capital Expenditures	$671K+306.7%	$165K+66.7%	$99K-48.7%	$193K	$0-100.0%	$84K+50.0%	$56K+250.0%	$16K
Free Cash Flow	$33.0M+18.2%	$27.9M+25.6%	$22.2M+19.6%	$18.6M+259.5%	$5.2M+32.4%	$3.9M-8.6%	$4.3M-74.8%	$17.0M
Investing Cash Flow	-$62.8M-1516.1%	-$3.9M+92.5%	-$51.5M-178.9%	$65.3M+239.5%	-$46.8M-283.3%	$25.5M+271.4%	-$14.9M-21.3%	-$12.3M
Financing Cash Flow	$11.9M+11.2%	$10.7M+286.5%	$2.8M+29.2%	$2.1M+1303.4%	-$178K-104.9%	$3.6M+419.9%	$695K+25.9%	$552K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

KNSA Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	85.6%-2.0pp	87.6%-2.0pp	89.6%+13.2pp	76.4%	N/A	N/A
Operating Margin	-10.8%-1.5pp	-9.3%-13.8pp	4.4%+410.8pp	-406.4%	N/A	N/A
Net Margin	-10.2%-15.4pp	5.2%-78.1pp	83.3%+493.0pp	-409.7%	N/A	N/A
Return on Equity	N/A	3.2%-43.1pp	46.3%	N/A	N/A	N/A
Return on Assets	-7.4%-10.1pp	2.7%-37.2pp	39.9%+107.7pp	-67.8%-21.7pp	-46.2%+17.4pp	-63.6%
Current Ratio	3.30-1.0	4.34-0.8	5.16+0.8	4.38-6.1	10.46+1.8	8.68
Debt-to-Equity	0.32+0.1	0.20+0.0	0.16-0.1	0.26+0.1	0.120.0	0.13
FCF Margin	6.0%+1.1pp	4.9%+2.3pp	2.6%+331.3pp	-328.8%	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	88.8%+0.7pp	88.1%+1.1pp	87.0%+1.6pp	85.4%-3.3pp	88.7%+1.9pp	86.8%-1.8pp	88.5%+2.1pp	86.5%
Operating Margin	13.3%+0.4pp	12.9%+3.2pp	9.6%+25.4pp	-15.8%-15.6pp	-0.1%+20.6pp	-20.7%-20.8pp	0.1%+16.4pp	-16.3%
Net Margin	10.2%-1.2pp	11.4%+5.2pp	6.2%+13.5pp	-7.2%-3.6pp	-3.6%+18.6pp	-22.2%-52.4pp	30.3%+50.9pp	-20.7%
Return on Equity	3.4%-0.2pp	3.6%+1.7pp	1.9%	N/A	N/A	N/A	5.8%	N/A
Return on Assets	2.6%-0.1pp	2.7%+1.3pp	1.4%+2.9pp	-1.5%-0.8pp	-0.7%+2.7pp	-3.4%-8.2pp	4.8%+7.7pp	-2.9%
Current Ratio	3.85+0.3	3.57-0.1	3.66+0.4	3.30-0.3	3.57-0.6	4.21-0.1	4.34-0.5	4.79
Debt-to-Equity	0.330.0	0.34+0.0	0.31-0.0	0.32+0.1	0.25+0.0	0.200.0	0.200.0	0.19
FCF Margin	18.3%+0.4pp	17.8%+1.7pp	16.1%+1.0pp	15.2%+10.4pp	4.8%-0.1pp	4.9%-0.2pp	5.1%-20.2pp	25.3%

Similar Companies

Hutchmed (China) Limited HCM

$2.5B

Supernus Pharma SUPN

$2.9B

Indivior Pharmaceuticals Inc INDV

$4.2B

Bausch Health Companies Inc BHC

$2.2B

Alvotech ALVO

$1.5B

Frequently Asked Questions

What is Kiniksa Pharmaceuticals International, plc's annual revenue?

Kiniksa Pharmaceuticals International, plc (KNSA) reported $423.2M in total revenue for fiscal year 2024. This represents a 56.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Kiniksa Pharmaceuticals International, plc's revenue growing?

Kiniksa Pharmaceuticals International, plc (KNSA) revenue grew by 56.6% year-over-year, from $270.3M to $423.2M in fiscal year 2024.

Is Kiniksa Pharmaceuticals International, plc profitable?

No, Kiniksa Pharmaceuticals International, plc (KNSA) reported a net income of -$43.2M in fiscal year 2024, with a net profit margin of -10.2%.

What is Kiniksa Pharmaceuticals International, plc's earnings per share (EPS)?

Kiniksa Pharmaceuticals International, plc (KNSA) reported diluted earnings per share of $-0.60 for fiscal year 2024. This represents a -400.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Kiniksa Pharmaceuticals International, plc's EBITDA?

Kiniksa Pharmaceuticals International, plc (KNSA) had EBITDA of -$43.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Kiniksa Pharmaceuticals International, plc's gross margin?

Kiniksa Pharmaceuticals International, plc (KNSA) had a gross margin of 85.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Kiniksa Pharmaceuticals International, plc's operating margin?

Kiniksa Pharmaceuticals International, plc (KNSA) had an operating margin of -10.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Kiniksa Pharmaceuticals International, plc's net profit margin?

Kiniksa Pharmaceuticals International, plc (KNSA) had a net profit margin of -10.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Kiniksa Pharmaceuticals International, plc's free cash flow?

Kiniksa Pharmaceuticals International, plc (KNSA) generated $25.4M in free cash flow during fiscal year 2024. This represents a 92.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Kiniksa Pharmaceuticals International, plc's operating cash flow?

Kiniksa Pharmaceuticals International, plc (KNSA) generated $25.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Kiniksa Pharmaceuticals International, plc's total assets?

Kiniksa Pharmaceuticals International, plc (KNSA) had $580.6M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Kiniksa Pharmaceuticals International, plc's capital expenditures?

Kiniksa Pharmaceuticals International, plc (KNSA) invested $277K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Kiniksa Pharmaceuticals International, plc spend on research and development?

Kiniksa Pharmaceuticals International, plc (KNSA) invested $111.6M in research and development during fiscal year 2024.

What is Kiniksa Pharmaceuticals International, plc's current ratio?

Kiniksa Pharmaceuticals International, plc (KNSA) had a current ratio of 3.30 as of fiscal year 2024, which is generally considered healthy.

What is Kiniksa Pharmaceuticals International, plc's debt-to-equity ratio?

Kiniksa Pharmaceuticals International, plc (KNSA) had a debt-to-equity ratio of 0.32 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Kiniksa Pharmaceuticals International, plc's return on assets (ROA)?

Kiniksa Pharmaceuticals International, plc (KNSA) had a return on assets of -7.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Kiniksa Pharmaceuticals International, plc's Piotroski F-Score?

Kiniksa Pharmaceuticals International, plc (KNSA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Kiniksa Pharmaceuticals International, plc's earnings high quality?

Kiniksa Pharmaceuticals International, plc (KNSA) has an earnings quality ratio of -0.59x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Kiniksa Pharmaceuticals International, plc?

Kiniksa Pharmaceuticals International, plc (KNSA) scores 66 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.